PerkinElmer (UK) Holdings Limited entered into an agreement to acquire Oxford Immunotec Global PLC (NasdaqGM:OXFD for approximately $560 million on January 7, 2021. Under the terms, PerkinElmer will pay $22 per share in cash for each outstanding ordinary share of Oxford. Under the terms of the agreement, the vesting of any restricted share units and options granted pursuant to the Oxford Immunotec Share Plans which are unvested will be accelerated to full vesting. PerkinElmer intends to finance the consideration through existing cash resources available to the PerkinElmer Group. Upon the closing of the transaction, Oxford Immunotec will become a privately held company and Oxford Immunotec’s ordinary shares will no longer be listed on any public market. Upon termination, Oxford will pay $5.9 million to PerkinElmer. The transaction is subject to approval of Oxford Immunotec’s shareholders, court approval of the Scheme and other customary closing conditions. The transaction was unanimously approved by the Board of Directors of both, PerkinElmer and Oxford. PerkinElmer has received irrevocable undertakings from all Oxford Immunotec Directors and named executive officers, whereby they have agreed to vote or procure votes in favour of the acquisition, representing approximately 1.3% of the issued and outstanding ordinary share capital of Oxford Immunotec. Perella Weinberg delivered an opinion that the acquisition is fair and favourable to the shareholders of Oxford Immunotec. As of January 29, 2021, the court meeting and the general meeting will be held on February 26, 2021. The transaction is expected to close in the first half of calendar 2021. In terms of financial impact, PerkinElmer expects the acquisition to be modestly accretive to non-GAAP earnings in year-one following the close, and PerkinElmer anticipates Oxford Immunotec’s sales growth will exceed that of its Diagnostics franchise for the foreseeable future. Perella Weinberg UK Limited and its affiliate Perella Weinberg Partners LP acted as financial advisors and fairness opinion providers to Oxford Immunotec. James Gubbins, Jack S. Bodner, Guy Dingley, Ansgar A. Simon, Jenna Wallace, Morag Peberdy, Scott D. Danzis, Stefanie A. Doebler, Joshua Gray, Daniel Pavin, Elizabeth H. Canter, Miranda Cole and Kristin E. Shaffer of Covington & Burling LLP acted as legal advisors to Oxford Immunotec. Georgeson LLC and Broadridge Financial Solutions Inc. acted as information agents to Oxford Imunotec. Computershare Trust Company, N.A. acted as transfer agent to Oxford Immunotec. Guggenheim Securities, LLC acted as financial advisor to PerkinElmer. Hal J. Leibowitz, Christopher D. Barnstable- Brown, Amy A. Null, R. Scott Kilgore, Julie Hogan Rodgers, Bruce S. Manheim Jr., Kirk J. Nahra, Steven D. Barrett, and Mark Nylen of Wilmer Cutler Pickering Hale and Dorr LLP; and Tom Brassington, Fiona Bantock and Karen Hughes of Hogan Lovells International LLP acted as legal advisors to PerkinElmer. Perella Weinberg UK will receive a $1.5 million fee upon the delivery of the fairness opinion and an additional fee of approximately $5 million upon the closing of the acquisition. Georgeson LLC will receive a payment of $0.015 million PerkinElmer (UK) Holdings Limited completed the acquisition of Oxford Immunotec Global PLC (NasdaqGM:OXFD) on March 8, 2021.On the Effective Date, in connection with the Implementation Agreement and the Acquisition, each of the eight previous non-executive directors of the Company (Richard A. Sandberg, Ronald Andrews Jr., Patrick J. Balthrop Sr., Patricia Randall, Mark Klausner, Herman Rosenman, James R. Tobin, and A. Scott Walton) voluntarily resigned from the board of directors of the Company on the Scheme becoming effective. On the Effective Date, Joel Goldberg became a director of the Company, joining Peter Wrighton-Smith on the board of directors of Oxford.